Clinical applications of CD34+ cell-selected peripheral blood stem cells

Therapeutic Apheresis

Volumn 7, Issue 3, 2003, Pages 298-304

  Kawabata, Y ^a   Hirokawa, M ^a   Komatsuda, A ^a   Sawada, Ken Ichi ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Allograft; Autograft; Autoimmune; CD34+ cell selection, Transplantation

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; RITUXIMAB;

ALLOGRAFT; ARTICLE; AUTOGRAFT; AUTOTRANSPLANTATION; BREAST CANCER; CANCER SURVIVAL; CELL SELECTION; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; FEASIBILITY STUDY; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HUMAN; IMMUNOPATHOLOGY; INCIDENCE; INFECTION RISK; LIVING DONOR; LYMPHOMA; MEDICAL TECHNOLOGY; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROGNOSIS; PURIFICATION; SURVIVAL TIME; SYSTEM ANALYSIS; TECHNIQUE; TREATMENT OUTCOME;

ANTIGENS, CD34; BONE MARROW PURGING; BONE MARROW TRANSPLANTATION; BREAST NEOPLASMS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; MALE; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0038148681     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.2003.00059.x     Document Type: Article

References (41)

1. Vogel W, Scheding S, Kanz L, Brugger W. Clinical Applications of CD34+ Peripheral Blood Progenitor Cells (PBPC). Stem Cells, 2000;18:87-92.
2. Bohbot A, Lioure B, Faradji A et al. Positive selection of CD34+ cells from cryopreserved peripheral blood stem cells after thawing: technical aspects and clinical use. Bone Marrow Transplant, 1996;17:259-64.
3. Koizumi K, Nishio M, Endo T et al. Large scale purification of human blood CD34+ cells from cryopreserved peripheral blood stem cells, using a nylon-fiber syringe system and immunomagnetic microspheres. Bone Marrow Transplant 2000;26:787-93.
4. Brugger W, Bross KJ, Glatt M, Weber F, Mertelsmann R, Kanz L. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994;83:636-40.
5. Gribben JG, Neuberg D, Freedman AS et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993;81:3449-57.
6. Rill DR, Santana VM, Roberts WM et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994;84:380-3.
7. Freedman AS, Neuberg D, Mauch P et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999;94:3325-33.
8. Zimmerman TM, Bender JG, Lee WJ et al. Large scale selection of CD34+ peripheral blood progenitors and expansion of neutrophil precursors for clinical applications. J Hematother 1996;5:247-53.
9. Tricot G, Gazitt Y, Leemhuis T et al. Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. Blood 1998;91:4489-95.
10. Shpall EJ, Jones RB, Bearman SI et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 1994;12:28-36.
11. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randoized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-7.
12. Vescio R, Schiller G, Stewart AK et al. Multicenter phase III trial to evaluate CD34+ selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood 1999;93:1858-68.
13. Stewart AK, Vescio R, Schiller G et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: Results of a multicenter randomized controlled trial. J Clin Oncol 2001;19:3771-9.
14. Gupta D, Bybee A, Cooke F et al. CD34+-selected peripheral blood progenitor cell transplantation in patients with multiple myeloma: tumour cell contamination and outcome. Br J Haematol 1999;104:166-77.
15. Lemoli RM, Fortuna A, Motta MR et al. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. Blood 1996;87:1625-34.
16. Gandhi M, Jestice H, Scott M et al. A comparison of CD34+ cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: a case controlled analysis. Bone Marrow Transplant 1999;24:369-75.
17. Moos M, Schulz R, Martin S, Benner A, Haas R. The remission status before and the PCR status after high dose therapy with peripheral blood stem cell support are prognostic factors for relapse free survival in patients with follicular non Hodgkin's lymphoma. Leukemia 1998;12:1971-6.
18. Paulus U, Schmitz N, Viehmann K, von Neuhoff N, Dreger P. Combined positive/negative selection for highly effective purging of PBPC grafts: towards clinical application in patients with B-CLL. Bone Marrow Transplant 1997;20:415-20.
19. Voso MT, Hohaus S, Moos M et al. Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content. Br J Haematol 1999;104:382-91.
20. Voso MT, Pantel G, Weis M et al. In vivo depletion B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol 2000;109:729-35.
21. Magni M, Di Nicola M, Devizzi L et al. Succesful in vivo purging of CD 34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000;96:864-9.
22. Beatty PG, Anasetti C, Hansen JA et al. Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. Blood 1993;81:249-53.
23. Uharek L, Gassmann W, Glass B, Steinmann J, Loeffler H, Mueller-Ruchholtz W. Influence of cell dose and graft-versus-host reactivity on rejection rates after allogeneic bone marrow transplantation. Blood 1992;79:1612-21.
24. Urbano-Ispizua A, Rozman C, Martinez C et al. Rapid engraftment without significant graft-versus-host disease after allogeneic transplantation of CD34+ selected cells from peripheral blood. Blood 1997;89:3967-73.
25. Marmont A, Horowitz MM, Gale RP et al. T cell depletion of HLA-identical transplants in leukemia. Blood 1991;78:2120-8.
26. Aversa F, Tabilio A, Velardi A et al. Treatment of high-risk acute leukemia with T cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998;339:1186-93.
27. Martinez C, Urbano-Ispizua A, Rozman C et al. Immune reconstitution following allogeneic peripheral blood progenitor cell transplantation: comparison of recipients of positive CD34+ selected grafts with recipients of unmanipulated grafts. Exp Hematol 1999;27:561-8.
28. Marmont AM. Stem cell transplantation for severe autoimmune disorders, with special reference to rheumatic diseases. J Rheumatol 1997;48(Suppl.):13-8.
29. McSweeney PA, Nash RA, Storb R, Furst DE, Gauthier J, Sullivan KM. Autologous stem cell transplantation for autoimmune diseases: issues in protocol development. J Rheumatol 1997;48(Suppl.):79-84.
30. Burt RK, Slavin S, Burns WH, Marmont AM. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? Blood 2002;99:768-84.
31. Tyndall A, Passweg J, Gratwohl A. Hematopoietic stem cell transplantation in the treatment of severe autoimmune diseases. Ann Rheum Dis 2001 2000;60:702-7.
32. Fassas A, Anagnostopoulos A, Kazis A et al. Autologous stem cell transplantation in progressive multiple scleraosis-An interium analysis of efficacy. J Clin Immunol 2000;20:24-30.
33. Bacigalupo A, Mordini N, Pitto A et al. Transplantation of HLA-mismatched CD34+ selected cells in patients with advanced malignancies: Severe immunodeficiency and related complications. Br J Hematol 1997;98:760-6.
34. Holmberg LA, Boeckh M, Hooper H et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 1999;94:4029-35.
35. Bilgrami S, Aslanzadeh J, Feingold JM et al. Cytomegalovirus viremia, viuria and disease after autologous peripheral blood stem cell transplantation: no need for surveillance. Bone Marrow Transplant 1999:24:69-73.
36. Ketterer N, Sonet A, Dumontet C et al. Toxicities after peripheral blood progenitor cell transplantation for lymphoid malignancies analysis of 300 cases in a single institution. Bone Marrow Transplant 1999;23:1309-15.
37. Van der Bij W, Torensma R, van Son WJ et al. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leukocytes. J Med Virol 1988;25:179-85.
38. Boeckh M, Stevens-Ayers T, Bowden RA. Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation. J Infect Dis 1996;174:907-12.
39. Manteiga R, Martino R, Sureda A et al. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem cell transplantation: a single-center experience. Bone Marrow Transplant 1998;22:899-904.
40. Nishio M, Koizumi K, Endo T, Fujimoto K, Koike T, Sawada K. Diminished T cell recovery after CD34+ selected autologous peripheral blood stem cell transplantation increases the risk of cytomegalovirus (CMV) infection. Haematologica 2001;86:667-8.
41. Reusser P, Attenhofer R, Hebart H, Helg C, Chapuis B, Einsele H. Cytomegalovirus-specific T cell immunity in recipients of autologous peripheral blood stem cell or bone marrow transplants. Blood 1997;89:3873-9.